Figure 1.

Persistence of resistance‐associated baseline polymorphisms and treatment‐emergent substitutions in GT 2a or 2b‐infected patients who experienced virologic failure. The percentage of VF patients with the designated baseline or treatment‐emergent substitution is shown for the baseline, time of VF, post‐treatment week 24, and post‐treatment week 48 time points. Columns denoted as “Any” include patients with any baseline polymorphism or treatment‐emergent substitution for NS3 or NS5A at signature resistance‐associated amino acid positions. Baseline polymorphisms L/M31 in NS5A were not included in the total “Any” count. Specific amino acid substitutions designated as “(any)” include any amino acid change from wild‐type in the total count